Innovus Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:INNV)

$0.18 0.00 (0.00 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$0.18
Today's Range$0.18 - $0.19
52-Week Range$0.08 - $0.39
Volume1.36 million shs
Average Volume828,016 shs
Market Capitalization$29.43 million
P/E Ratio-2.50
Dividend YieldN/A
Beta4.41

About Innovus Pharmaceuticals (OTCMKTS:INNV)

Innovus Pharmaceuticals logoInnovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe.

Receive INNV News and Ratings via Email

Sign-up to receive the latest news and ratings for INNV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:INNV
CUSIPN/A
Phone858-964-5123

Debt

Debt-to-Equity RatioN/A
Current Ratio0.64%
Quick Ratio0.46%

Price-To-Earnings

Trailing P/E Ratio-2.50107127553207
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.82 million
Price / Sales5.97
Cash FlowN/A
Price / CashN/A
Book Value$0.01 per share
Price / Book17.51

Profitability

Trailing EPS($0.07)
Net Income$-13,700,000.00
Net Margins-102.95%
Return on Equity-330.39%
Return on Assets-72.75%

Miscellaneous

Employees5
Outstanding Shares164,430,000

Innovus Pharmaceuticals (OTCMKTS:INNV) Frequently Asked Questions

What is Innovus Pharmaceuticals' stock symbol?

Innovus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "INNV."

How were Innovus Pharmaceuticals' earnings last quarter?

Innovus Pharmaceuticals Inc (OTCMKTS:INNV) issued its earnings results on Tuesday, November, 14th. The company reported ($0.01) earnings per share for the quarter. The company earned $2.22 million during the quarter. Innovus Pharmaceuticals had a negative net margin of 102.95% and a negative return on equity of 330.39%. View Innovus Pharmaceuticals' Earnings History.

Who are some of Innovus Pharmaceuticals' key competitors?

Who are Innovus Pharmaceuticals' key executives?

Innovus Pharmaceuticals' management team includes the folowing people:

  • Henry J. Esber Ph.D., Chairman of the Board (Age 78)
  • Bassam B. Damaj Ph.D., President, Chief Executive Officer, Director (Age 48)
  • Rauly Gutierrez CPA, Principal Financial Officer, Principal Accounting Officer
  • Randy J. Berholtz Esq. J.D., Executive Vice President, General Counsel, Secretary (Age 53)
  • Vivian H. Liu, Director (Age 55)
  • Ziad Mirza M.D., Director (Age 54)

How do I buy Innovus Pharmaceuticals stock?

Shares of Innovus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Innovus Pharmaceuticals' stock price today?

One share of Innovus Pharmaceuticals stock can currently be purchased for approximately $0.18.

How big of a company is Innovus Pharmaceuticals?

Innovus Pharmaceuticals has a market capitalization of $29.43 million and generates $4.82 million in revenue each year. The company earns $-13,700,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. Innovus Pharmaceuticals employs 5 workers across the globe.

How can I contact Innovus Pharmaceuticals?

Innovus Pharmaceuticals' mailing address is 8845 Rehco Road, San Diego CA, 92122. The company can be reached via phone at 858-964-5123 or via email at [email protected]


MarketBeat Community Rating for Innovus Pharmaceuticals (INNV)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  103
MarketBeat's community ratings are surveys of what our community members think about Innovus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Innovus Pharmaceuticals (OTCMKTS:INNV) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Innovus Pharmaceuticals (OTCMKTS:INNV) Earnings History and Estimates Chart

Earnings by Quarter for Innovus Pharmaceuticals (OTCMKTS:INNV)

Innovus Pharmaceuticals (OTCMKTS INNV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($0.01)$2.22 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.01)$2.04 millionViewN/AView Earnings Details
5/12/2017Q1 2017($0.02)$2.18 millionViewN/AView Earnings Details
3/6/2017Q4 2016($0.02)$1.69 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.01)$1.88 millionViewN/AView Earnings Details
8/15/2016Q2 2016($0.05)$1.02 millionViewN/AView Earnings Details
5/16/2016Q1 2016($0.02)$0.23 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Innovus Pharmaceuticals (OTCMKTS:INNV) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.04 EPS

Dividends

Dividend History for Innovus Pharmaceuticals (OTCMKTS:INNV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Innovus Pharmaceuticals (OTCMKTS INNV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.14%
Insider Trades by Quarter for Innovus Pharmaceuticals (OTCMKTS:INNV)

Innovus Pharmaceuticals (OTCMKTS INNV) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/23/2017Henry Jemil EsberDirectorBuy100,000$0.09$9,000.00View SEC Filing  
11/22/2017Randy BerholtzEVPBuy16,880$0.10$1,688.00View SEC Filing  
6/12/2013Bassam DamajCEOBuy416,841$0.32$133,389.12View SEC Filing  
2/2/2013Bassam DamajCEOBuy250,406$0.48$120,194.88View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Innovus Pharmaceuticals (OTCMKTS INNV) News Headlines

Source:
DateHeadline
Emerging Developments: Singlepoint and Innovus Pharmaceuticals - A Look Ahead into 2018Emerging Developments: Singlepoint and Innovus Pharmaceuticals - A Look Ahead into 2018
finance.yahoo.com - February 23 at 10:11 AM
Innovus Pharma Announces the Complete Repayment in Cash of its Financial Obligations from its Acquisition of its Beyond Human® AssetsInnovus Pharma Announces the Complete Repayment in Cash of its Financial Obligations from its Acquisition of its Beyond Human® Assets
finance.yahoo.com - February 22 at 9:58 AM
SeeThruEquity Issues Update on Innovus Pharmaceuticals (INNV) with Target Price of $0.70SeeThruEquity Issues Update on Innovus Pharmaceuticals (INNV) with Target Price of $0.70
finance.yahoo.com - February 13 at 4:57 PM
Innovus Pharma Announces the Publication of a Successful Clinical Trial in Overactive Bladder and Urine Incontinence Patients for its UriVarx® ProductInnovus Pharma Announces the Publication of a Successful Clinical Trial in Overactive Bladder and Urine Incontinence Patients for its UriVarx® Product
finance.yahoo.com - February 7 at 8:40 AM
Innovus Pharma Expands Its Sales Channels Through an Alliance with Wellmed, LP to Access Their Extensive Direct Mailing Network of 500,000 Current CustomersInnovus Pharma Expands Its Sales Channels Through an Alliance with Wellmed, LP to Access Their Extensive Direct Mailing Network of 500,000 Current Customers
finance.yahoo.com - February 2 at 8:37 AM
Two Innovus Pharma Products Officially Listed in OTC Section of the RED BOOK™Two Innovus Pharma Products Officially Listed in OTC Section of the RED BOOK™
finance.yahoo.com - December 14 at 11:07 AM
Contrasting Innovus Pharmaceuticals (INNV) and Tonix Pharmaceuticals (TNXP)Contrasting Innovus Pharmaceuticals (INNV) and Tonix Pharmaceuticals (TNXP)
www.americanbankingnews.com - December 13 at 3:53 PM
Head to Head Survey: Innovus Pharmaceuticals (INNV) and Echo Therapeutics (ECTE)Head to Head Survey: Innovus Pharmaceuticals (INNV) and Echo Therapeutics (ECTE)
www.americanbankingnews.com - December 11 at 1:38 PM
Comparing Innovus Pharmaceuticals (INNV) & Tonix Pharmaceuticals (TNXP)Comparing Innovus Pharmaceuticals (INNV) & Tonix Pharmaceuticals (TNXP)
www.americanbankingnews.com - December 10 at 9:08 PM
Reviewing Innovus Pharmaceuticals (INNV) and Echo Therapeutics (ECTE)Reviewing Innovus Pharmaceuticals (INNV) and Echo Therapeutics (ECTE)
www.americanbankingnews.com - December 9 at 7:18 PM
Contrasting Echo Therapeutics (ECTE) & Innovus Pharmaceuticals (INNV)Contrasting Echo Therapeutics (ECTE) & Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - December 9 at 11:54 AM
Tonix Pharmaceuticals (TNXP) vs. Innovus Pharmaceuticals (INNV) Head-To-Head ReviewTonix Pharmaceuticals (TNXP) vs. Innovus Pharmaceuticals (INNV) Head-To-Head Review
www.americanbankingnews.com - December 8 at 3:50 PM
Head to Head Contrast: Innovus Pharmaceuticals (INNV) and Tonix Pharmaceuticals (TNXP)Head to Head Contrast: Innovus Pharmaceuticals (INNV) and Tonix Pharmaceuticals (TNXP)
www.americanbankingnews.com - December 6 at 1:28 AM
Comparing Tonix Pharmaceuticals (TNXP) & Innovus Pharmaceuticals (INNV)Comparing Tonix Pharmaceuticals (TNXP) & Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - December 5 at 9:34 AM
Head to Head Comparison: Echo Therapeutics (ECTE) versus Innovus Pharmaceuticals (INNV)Head to Head Comparison: Echo Therapeutics (ECTE) versus Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - December 5 at 3:32 AM
Reviewing Tonix Pharmaceuticals (TNXP) and Innovus Pharmaceuticals (INNV)Reviewing Tonix Pharmaceuticals (TNXP) and Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - December 3 at 1:48 AM
Reviewing Echo Therapeutics (ECTE) & Innovus Pharmaceuticals (INNV)Reviewing Echo Therapeutics (ECTE) & Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - November 30 at 7:46 PM
Echo Therapeutics (ECTE) versus Innovus Pharmaceuticals (INNV) Financial AnalysisEcho Therapeutics (ECTE) versus Innovus Pharmaceuticals (INNV) Financial Analysis
www.americanbankingnews.com - November 30 at 1:28 AM
Comparing Innovus Pharmaceuticals (INNV) and Tonix Pharmaceuticals (TNXP)Comparing Innovus Pharmaceuticals (INNV) and Tonix Pharmaceuticals (TNXP)
www.americanbankingnews.com - November 28 at 11:40 AM
Critical Review: Innovus Pharmaceuticals (INNV) versus Tonix Pharmaceuticals Holding Corp. (TNXP)Critical Review: Innovus Pharmaceuticals (INNV) versus Tonix Pharmaceuticals Holding Corp. (TNXP)
www.americanbankingnews.com - November 24 at 1:20 PM
Innovus Pharmaceuticals, Inc. (INNV) Upgraded at Zacks Investment ResearchInnovus Pharmaceuticals, Inc. (INNV) Upgraded at Zacks Investment Research
www.americanbankingnews.com - November 23 at 10:40 PM
Critical Analysis: Echo Therapeutics (ECTE) versus Innovus Pharmaceuticals (INNV)Critical Analysis: Echo Therapeutics (ECTE) versus Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - November 22 at 3:42 PM
SeeThruEquity Issues Update on Innovus Pharmaceuticals (INNV) with a Price Target of $0.65SeeThruEquity Issues Update on Innovus Pharmaceuticals (INNV) with a Price Target of $0.65
finance.yahoo.com - November 17 at 7:23 AM
Comparing Tonix Pharmaceuticals Holding Corp. (TNXP) & Innovus Pharmaceuticals (INNV)Comparing Tonix Pharmaceuticals Holding Corp. (TNXP) & Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - November 16 at 3:38 PM
Financial Comparison: Innovus Pharmaceuticals (INNV) and Echo Therapeutics (ECTE)Financial Comparison: Innovus Pharmaceuticals (INNV) and Echo Therapeutics (ECTE)
www.americanbankingnews.com - November 16 at 1:08 PM
Critical Analysis: Tonix Pharmaceuticals Holding Corp. (TNXP) vs. Innovus Pharmaceuticals (INNV)Critical Analysis: Tonix Pharmaceuticals Holding Corp. (TNXP) vs. Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - November 15 at 5:27 PM
Head to Head Contrast: Tonix Pharmaceuticals Holding Corp. (TNXP) versus Innovus Pharmaceuticals (INNV)Head to Head Contrast: Tonix Pharmaceuticals Holding Corp. (TNXP) versus Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - November 15 at 3:30 PM
Innovus Pharmaceuticals, Inc. (INNV) Posts  Earnings ResultsInnovus Pharmaceuticals, Inc. (INNV) Posts Earnings Results
www.americanbankingnews.com - November 15 at 12:54 PM
Innovus Pharma Announces Agreement with ACON Laboratories, Inc.Innovus Pharma Announces Agreement with ACON Laboratories, Inc.
finance.yahoo.com - November 9 at 6:49 AM
Innovus Pharmaceuticals to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 14, 2017Innovus Pharmaceuticals to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 14, 2017
finance.yahoo.com - November 7 at 4:21 AM

SEC Filings

Innovus Pharmaceuticals (OTCMKTS:INNV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Innovus Pharmaceuticals (OTCMKTS INNV) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.